Identification of Serum Proteins Related to Adverse Effects Induced by Docetaxel Infusion from Protein Expression Profiles of Serum Using SELDI ProteinChip System

摘要: Background: For the development of quick and easy methods for screening identifying treatment- responsive proteins, we determined protein expression profile serum after docetaxel infusion using a surface- enhanced laser desorption/ionization time-of-flight mass spectroscopy (SELDI TOF-MS) system. Materials Methods: Blood from breast cancer patients was collected before 4, 8, 24 48 hours infusion. The by SELDI TOF-MS relative levels target proteins were compared during time-course injection. Results: We identified two representative with molecular weights 7790 Da 9285 Da. high weight kininogen, apolipoprotein A-II. These had similar patterns in 5 patients, except one patient who experienced severe, acute, adverse effects. Conclusion: results suggest that profiles represent useful data identification treatment-responsive proteins. Docetaxel is key drug used to treat cancer. As hydrophobic, polysorbate 80 ethanol are as solvents. Some experience acute effects, including anaphylactoid reactions, may develop shock. Several reports these effects caused solvent, which contains (1, 2). However, mechanisms unknown. One approach determine causing analyze Pharmacokinetics pharmacodynamics important areas research clinical pharmacology metabolism host responses order predict response treatment. Recently, DNA chip technology, such microarrays cDNA arrays, has been promising have reported studies irinotecan other drugs (3-5), there no doubt this genetic could be potential information alone cannot perfectly treatment, because genes do not act themselves. Genes exert their effect through transcription translation. Thus, analysis Until recently, ideal tools available profiles. Although two- dimensional electrophoresis purpose, it labor-intensive capable high-throughput